Tonix Pharmaceuticals Holding Corp. Q2 2026 Earnings Recap

Tonix Pharmaceuticals' stock gained modestly by 2.6% post-earnings, reflecting steady early traction in the TONMYA launch but no clear upside surprise. While sales growth was impressive quarter-over-quarter, cautious coverage and access expansion temper enthusiasm and suggest the story remains in early innings.

Key Takeaways

• TONMYA net sales reached approximately $11 million in Q2 2026, nearly tripling the first quarter’s sales, driven by increased prescriptions (+100% QoQ), new patient starts (+36% QoQ), and refills (+207% QoQ).
• Coverage currently stands at 136 million lives (43% of U.S. covered lives), set to increase to about 145 million (46%) from January 2027 with managed Medicare deal activation.
• Sales gross-to-net trends remain volatile due to channel mix and prior authorization dynamics; fluctuations expected through year-end.
• Pipeline progress includes enrollment of the first patient in TNX-102 SL for Major Depressive Disorder and a positive FDA Type C meeting for TNX-4800 Lyme disease prevention, with Phase II enrollment planned for early 2027.
• Despite encouraging launch metrics, market reaction suggests investors are awaiting broader coverage and sustained sales momentum before committing fully.